Frequency of G2677T/A and C3435T polymorphisms of mdr1 gene in preeclamptic women

Ginekologia Polska

Volumn 84, Issue 9, 2013, Pages 781-787

  Bogacz, Anna ^a,b   Mrozikiewicz, Przemyslaw M ^a,b   Deka Pawlik, Donata ^a   Seremak Mrozikiewicz, Agnieszka ^a   Bartkowiak Wieczorek, Joanna ^a,b   Barlik, Magdalena ^a   Drews, Krzysztof ^a   Kowalska, Aleksandra ^a,b   Grzeskowiak, Edmund ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF NATURAL FIBRES AND MEDICINAL PLANTS   (Poland)

Author keywords

Genetic polymorphism; MDR1 gene; P glycoprotein; Preeclampsia

Indexed keywords

EID: 84888344797     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1640     Document Type: Article

References (27)

1. Mutter W, Karumanchi S. Molecular mechanisms of preeclampsia. Microvasc Res. 2008, 75, 1-8.
2. Turner J. Diagnosis and management of pre-eclampsia: an update. Int J Womens Health. 2010, 2, 327-337.
3. Seremak-Mrozikiewicz A. Significance of genetic polymorphism investigations in pregnancy complications. Arch Perinatal Med. 2013, 19, 7-11.
4. Allen V, Joseph K, Murphy K, [et al.]. The effect of hypertensive disorders in pregnancy on small for gestational age and stillbirth: a population based study. BMC Pregnancy Childbirth. 2004, 4, 17.
5. Kozlowska-Rup D, Czekaj P. Barrier role of ABC family of proteins in human placenta. Ginekol Pol. 2011, 82, 56-63.
6. Mégarbane B, Alhaddad H. Can P-glycoprotein expression on malignant tumor tissues predict opioid transport at the blood-brain barrier in cancer patients? Pharmacol Rep. 2013, 65, 235- 236.
7. Behravan J, Piquette-Miller M. Drug transport across the placenta, role of the ABC drug efflux transporters. Expert Opin Drug Metab Toxicol. 2007, 3, 819-830.
8. Myllynen P, Immonen E, Kummu M, Vahakangas S. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin Drug Metab Toxicol. 2009, 5, 1483-1499.
9. Sun M, Kingdom J, Baczyk D, [et al.]. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006, 27, 602-609.
10. Bazrafshani M, Poulton K, Mahmoodi M. A linkage and association analysis study in the multidrug resistance gene 1 (mdr1) in renal patients. Int J Mol Epidemiol Genet. 2012, 3, 314- 320.
11. Kimchi-Sarfaty C, Oh J, Kim I, [et al.]. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007, 315, 525-528.
12. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol. 2001, 98, 177-185.
13. Cascorbi I, Gerloff T, Johne A, [et al.]. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001, 69, 169-174.
14. Hemauer S, Nanovskaya T, Abdel-Rahman S, [et al.]. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol. 2010, 79, 921-925.
15. Hitzl M, Schaeffeler E, Hocher B, [et al.]. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics. 2004, 14, 309-318.
16. Tanabe M, Ieiri I, Nagata N, [et al.]. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001, 297, 1137-1143.
17. Rahi M, Heikkinen T, Härtter S, [et al.]. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol. 2007, 21, 751-756.
18. Michalska-Krzanowska G, Stasiak-Pikula E, Pakulski C. Effect of induced pregnancy hypertension on the permeability of the blood-brain barrier. Borgis Anest Intens Ter. 2001, 237- 239.
19. Redman C, Sargent I. Pre-eclampsia, the placenta and the maternal systemic inflammatory response - a review. Placenta. 2003, 24, 21-27.
20. Ameyaw M, Regateiro F, Li T, [et al.]. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001, 11, 217- 221.
21. Schaeffeler E, Eichelbaum M, Brinkmann U, [et al.]. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001, 358, 383-384.
22. Balram C, Sharma A, Sivathasan C, [et al.]. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol. 2003, 56, 78-83.
23. Yi S, Hong M, Lim H, [et al.]. The mutant a allele function in exon 21 G2677T/A of human MDR1 gene. Clin Pharmacol Ther. 2004; doi:10.1016/j.clpt.2003.11.255.
24. Kim R, Leake B, Choo E, [et al.]. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001, 70, 189-199.
25. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target. 2012, 20, 736-763.
26. Eshkoli T, Sheiner E, Ben-Zvi Z, [et al.]. Drug transport across the placenta. Curr Pharm Biotechnol. 2011, 12, 707-714.
27. Wu C, Hsieh C, Wu Y. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm. 2011, 8, 1996-2011.